Lineage Cell Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	35.94	40.79	45.79	35.44	11.36	55.74
Short-Term Investments	17.44	14.99	2.02	0.05	46.52	2.62
Cash & Short-Term Investments	53.38	55.78	47.81	35.49	57.88	58.36
Cash Growth	11.43%	16.68%	34.69%	-38.67%	-0.83%	40.41%
Accounts Receivable	0.81	0.89	0.64	0.75	0.3	50.84
Other Current Assets	1.98	2.49	2.55	2.2	1.83	2.35
Total Current Assets	56.16	59.16	51	38.44	60	111.55
Net Property, Plant & Equipment	4.62	4.7	4.4	4.77	5.67	4.87
Other Intangible Assets	31.7	31.7	46.54	46.56	46.69	46.82
Goodwill	10.67	10.67	10.67	10.67	10.67	10.67
Other Long-Term Assets	6.37	6.36	0.61	0.58	0.63	0.63
Total Assets	109.53	112.58	113.22	101.02	123.66	174.55
Accounts Payable	5.57	7.18	5.44	6.27	8.61	27.97
Current Portion of Leases	0.87	0.85	1.15	0.88	0.95	0.83
Unearned Revenue	1.72	3.33	7.39	10.81	9.42	18.12
Other Current Liabilities	-	-	-	-	-	0.2
Total Current Liabilities	8.15	11.37	13.98	17.96	18.98	47.12
Long-Term Leases	1.53	1.57	1.36	2.07	2.94	1.97
Other Long-Term Liabilities	47.16	56.31	20.87	18.97	29.8	34.56
Total Long-Term Liabilities	48.69	57.87	22.23	21.04	32.75	36.53
Total Liabilities	56.84	69.24	36.21	39	51.73	83.65
Common Stock	529.66	515.47	484.72	451.34	440.28	434.53
Accumulated Other Comprehensive Income	-3.97	-3.92	-2.88	-3.07	-3.57	-5.21
Retained Earnings	-471.81	-467	-403.47	-384.86	-363.37	-337.1
Total Common Shareholders' Equity	53.88	44.55	78.38	63.42	73.34	92.22
Minority Interest	-1.18	-1.2	-1.37	-1.4	-1.4	-1.32
Shareholders' Equity	52.7	43.35	77.01	62.02	71.94	90.9
Total Liabilities & Equity	109.53	112.58	113.22	101.02	123.66	174.55
Total Debt	2.39	2.42	2.51	2.95	3.9	2.8
Net Cash (Debt)	50.99	53.36	45.29	32.54	53.98	55.56
Net Cash Growth	-4.45%	17.82%	39.19%	-39.72%	-2.84%	45.21%
Net Cash Per Share	0.21	0.23	0.23	0.19	0.32	0.34
Book Value	53.88	44.55	78.38	63.42	73.34	92.22
Book Value Per Share	0.23	0.19	0.39	0.37	0.43	0.56
Tangible Book Value	11.5	2.18	21.17	6.19	15.98	34.73
Tangible Book Value Per Share	0.05	0.01	0.11	0.04	0.09	0.21

Updated May 12, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q